Share Price and Basic Stock Data
Last Updated: November 22, 2025, 3:11 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hindustan Agrigenetics Ltd operates within the floriculture industry, focusing on the cultivation and distribution of flowers. As of the latest reporting period, the company’s stock price stood at ₹55.5, with a market capitalization of ₹24.4 Cr. Revenue trends indicate a volatile performance in recent quarters, with sales recorded at ₹0.04 Cr in June 2022, declining to ₹0.00 Cr in September 2022 and March 2023, before recovering to ₹0.04 Cr in June 2023. The company has maintained a modest annual revenue of around ₹0.07 Cr for FY 2024 and FY 2025, demonstrating a slight growth trajectory. The fluctuations in sales, particularly the absence of revenue in multiple quarters, raises concerns about the company’s operational stability. The reported operating profit margin (OPM) has shown extreme variability, with a peak of 300% in December 2023, but it also hit a low of -914.29% in FY 2023, reflecting inefficiencies in cost management and pricing strategies.
Profitability and Efficiency Metrics
Profitability metrics for Hindustan Agrigenetics Ltd reveal significant challenges, with a reported net profit of ₹0.04 Cr for the latest period. The company’s return on equity (ROE) stood at a low 3.61%, while return on capital employed (ROCE) was slightly better at 3.53%. The company faces an extraordinary interest coverage ratio of -23.78x, indicating a severe inability to cover interest expenses, which raises red flags about its financial health. The operating profit margins have fluctuated widely, with OPM reaching a high of 300% in December 2023 but also experiencing negative figures due to rising expenses. For instance, total expenses jumped to ₹0.71 Cr in FY 2023, significantly impacting profitability. The negative trends in profitability, alongside a high price-to-earnings (P/E) ratio of 271, suggest that the stock may be overvalued relative to its earnings potential, raising concerns among investors about future profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Agrigenetics Ltd presents a mixed picture. The company reported no borrowings, which could be seen as a strength in terms of financial leverage; however, the absence of reserves raises concerns about liquidity and financial flexibility. The company’s current ratio of 330.73 indicates an exceptionally strong liquidity position, suggesting that it can easily meet short-term obligations. However, the negative interest coverage ratio reflects challenges in generating sufficient earnings to cover interest expenses. The book value per share, including revaluation reserves, was reported at ₹27.32 for FY 2025, which is significantly higher than the current stock price, indicating potential undervaluation. Nevertheless, the company’s financial health is undermined by its inability to generate consistent profits, as seen in the trailing twelve months (TTM) net profit margin of -395.59%. These figures highlight both strengths in liquidity and weaknesses in profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Agrigenetics Ltd shows a significant presence of public shareholders, comprising 64.71% of the total ownership. Promoters hold 25.35%, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) account for 0.43% and 1.08%, respectively. Over the past year, the promoters’ stake has decreased from 29.42% in December 2022 to 8.20% by March 2025, which could signal diminishing confidence in the company’s future prospects. Additionally, the number of shareholders has increased to 7,669, suggesting growing interest from the public. However, the low institutional ownership may indicate a lack of confidence from larger investors, potentially impacting the stock’s performance. The increase in public shareholding and the decline in promoter holdings could reflect a shift in investor sentiment, as stakeholders assess the company’s operational challenges and profitability uncertainties.
Outlook, Risks, and Final Insight
Hindustan Agrigenetics Ltd faces a challenging outlook characterized by fluctuating revenues and profitability issues. The company’s ability to stabilize sales and manage costs will be critical in determining its future success. Risks include its negative interest coverage ratio, which suggests potential liquidity issues, and the significant decline in promoter shareholding, indicating waning confidence from key stakeholders. Additionally, the extreme variability in operating profit margins could deter investors seeking stable returns. Conversely, the company’s robust liquidity position and lack of debt provide some buffer against financial distress. If Hindustan Agrigenetics can successfully implement strategies to improve operational efficiency and restore profitability, it may regain investor confidence. However, without concrete steps to address these issues, the company risks continued instability in both its financial performance and market perception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hindustan Agrigenetics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Nagarjuna Agri Tech Ltd | 41.5 Cr. | 44.3 | 83.3/29.4 | 76.9 | 7.73 | 0.00 % | 1.34 % | 1.34 % | 10.0 |
| Hindustan Agrigenetics Ltd | 24.1 Cr. | 54.7 | 103/48.8 | 267 | 0.00 % | 3.53 % | 3.61 % | 10.0 | |
| Elegant Floriculture & Agrotech (India) Ltd | 13.1 Cr. | 5.11 | 11.6/4.38 | 4.26 | 9.94 | 0.00 % | 5.85 % | 5.22 % | 10.0 |
| Industry Average | 0 Cr | 34.70 | 116.05 | 8.84 | 0.00% | 3.57% | 3.39% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 |
| Expenses | 0.33 | 0.05 | 0.11 | 0.12 | 0.03 | 0.07 | -0.06 | 0.01 | 0.01 | 0.00 | 0.24 | 0.69 | 0.14 |
| Operating Profit | -0.29 | -0.05 | -0.08 | -0.12 | 0.01 | -0.07 | 0.09 | -0.01 | 0.03 | 0.00 | -0.21 | -0.69 | -0.10 |
| OPM % | -725.00% | -266.67% | 25.00% | 300.00% | 75.00% | -700.00% | -250.00% | ||||||
| Other Income | 0.09 | 0.14 | 0.15 | 0.03 | 0.14 | 0.16 | 0.15 | 0.15 | 0.02 | 0.15 | 0.24 | 0.18 | 0.51 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.08 | 0.23 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.07 | 0.22 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| EPS in Rs |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Agrigenetics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Jun 2025, the value is 0.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Mar 2025) to 0.14 Cr., marking a decrease of 0.55 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.10 Cr.. The value appears strong and on an upward trend. It has increased from -0.69 Cr. (Mar 2025) to -0.10 Cr., marking an increase of 0.59 Cr..
- For OPM %, as of Jun 2025, the value is -250.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -250.00%, marking a decrease of 250.00%.
- For Other Income, as of Jun 2025, the value is 0.51 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.51 Cr., marking an increase of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.00. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.19 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 |
| Expenses | 0.12 | 0.26 | 0.12 | 0.16 | 0.21 | 0.22 | 0.59 | 0.19 | 0.23 | 0.71 | 0.37 | 1.10 | 1.07 |
| Operating Profit | -0.06 | -0.20 | -0.06 | -0.10 | -0.16 | -0.16 | -0.40 | -0.13 | -0.17 | -0.64 | -0.30 | -1.02 | -1.00 |
| OPM % | -100.00% | -333.33% | -100.00% | -166.67% | -320.00% | -266.67% | -210.53% | -216.67% | -283.33% | -914.29% | -428.57% | -1,275.00% | -1,428.57% |
| Other Income | 0.05 | 0.30 | 0.95 | 0.28 | 0.19 | 0.04 | 0.04 | -0.05 | 0.06 | 10.55 | 0.96 | 0.76 | 1.08 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.03 | 0.09 | 0.88 | 0.17 | 0.02 | -0.13 | -0.37 | -0.18 | -0.11 | 9.91 | 0.60 | -0.31 | 0.04 |
| Tax % | 133.33% | 0.00% | 25.00% | 35.29% | 3,100.00% | -7.69% | -186.49% | -16.67% | -9.09% | 0.50% | 23.33% | 0.00% | |
| Net Profit | -0.07 | 0.09 | 0.66 | 0.11 | -0.59 | -0.12 | 0.33 | -0.15 | -0.10 | 9.86 | 0.47 | -0.31 | 0.04 |
| EPS in Rs | |||||||||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 228.57% | 633.33% | -83.33% | -636.36% | 79.66% | 375.00% | -145.45% | 33.33% | 9960.00% | -95.23% | -165.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.76% | -716.67% | -553.03% | 716.02% | 295.34% | -520.45% | 178.79% | 9926.67% | -10055.23% | -70.72% |
Hindustan Agrigenetics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Days | -5,170.83 | -5,353.33 | -730.00 | -243.33 | -365.00 | -608.33 | 883.68 | -4,501.67 | -36,925.83 | -1,668.57 | 730.00 | 11,543.12 |
| ROCE % | -3.51% | -2.00% | 33.61% | 0.00% | 0.81% | -1.95% | -13.46% | -5.99% | -7.80% | 144.88% | 2.07% | -3.53% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Diluted EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Cash EPS (Rs.) | -0.61 | 1.15 | 22.41 | -0.21 | -0.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 27.32 | 27.65 | 26.58 | 4.17 | 4.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 27.32 | 28.02 | 26.95 | 4.55 | 4.77 |
| Revenue From Operations / Share (Rs.) | 0.17 | 2.35 | 24.43 | 0.28 | 0.13 |
| PBDIT / Share (Rs.) | -0.59 | 1.46 | 22.52 | -0.24 | -0.40 |
| PBIT / Share (Rs.) | -0.68 | 1.38 | 22.52 | -0.25 | -0.40 |
| PBT / Share (Rs.) | -0.69 | 1.38 | 22.52 | -0.25 | -0.40 |
| Net Profit / Share (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| PBDIT Margin (%) | -342.41 | 62.20 | 92.19 | -85.45 | -288.85 |
| PBIT Margin (%) | -388.97 | 58.64 | 92.17 | -87.40 | -295.28 |
| PBT Margin (%) | -399.09 | 58.64 | 92.17 | -87.40 | -295.28 |
| Net Profit Margin (%) | -395.59 | 45.44 | 91.71 | -76.62 | -238.42 |
| Return on Networth / Equity (%) | -2.53 | 3.85 | 84.29 | -5.28 | -7.52 |
| Return on Capital Employeed (%) | -2.42 | 4.91 | 83.54 | -5.53 | -8.59 |
| Return On Assets (%) | -2.45 | 3.68 | 79.74 | -1.18 | -4.94 |
| Asset Turnover Ratio (%) | 0.01 | 0.08 | 1.05 | 0.02 | 0.02 |
| Current Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Quick Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Interest Coverage Ratio (X) | -23.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | -26.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 24.41 | 13.01 | -8.02 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 316.56 | 12.59 | -0.74 | 0.00 | 0.00 |
| EV / EBITDA (X) | -92.45 | 20.24 | -0.80 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 383.23 | 21.77 | 0.20 | 0.00 | 0.00 |
| Price / BV (X) | 2.46 | 1.85 | 0.19 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 383.71 | 21.77 | 0.20 | 0.00 | 0.00 |
| EarningsYield | -0.01 | 0.02 | 4.44 | 0.00 | 0.00 |
After reviewing the key financial ratios for Hindustan Agrigenetics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.15 (Mar 24) to -0.61, marking a decrease of 1.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 27.65 (Mar 24) to 27.32, marking a decrease of 0.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 28.02 (Mar 24) to 27.32, marking a decrease of 0.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.17. It has decreased from 2.35 (Mar 24) to 0.17, marking a decrease of 2.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.59. This value is below the healthy minimum of 2. It has decreased from 1.46 (Mar 24) to -0.59, marking a decrease of 2.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.68. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.68, marking a decrease of 2.06.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.69, marking a decrease of 2.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 2. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For PBDIT Margin (%), as of Mar 25, the value is -342.41. This value is below the healthy minimum of 10. It has decreased from 62.20 (Mar 24) to -342.41, marking a decrease of 404.61.
- For PBIT Margin (%), as of Mar 25, the value is -388.97. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -388.97, marking a decrease of 447.61.
- For PBT Margin (%), as of Mar 25, the value is -399.09. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -399.09, marking a decrease of 457.73.
- For Net Profit Margin (%), as of Mar 25, the value is -395.59. This value is below the healthy minimum of 5. It has decreased from 45.44 (Mar 24) to -395.59, marking a decrease of 441.03.
- For Return on Networth / Equity (%), as of Mar 25, the value is -2.53. This value is below the healthy minimum of 15. It has decreased from 3.85 (Mar 24) to -2.53, marking a decrease of 6.38.
- For Return on Capital Employeed (%), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 10. It has decreased from 4.91 (Mar 24) to -2.42, marking a decrease of 7.33.
- For Return On Assets (%), as of Mar 25, the value is -2.45. This value is below the healthy minimum of 5. It has decreased from 3.68 (Mar 24) to -2.45, marking a decrease of 6.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 3. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Quick Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 2. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -23.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -23.78, marking a decrease of 23.78.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -26.77. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -26.77, marking a decrease of 26.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 24.41. It has increased from 13.01 (Mar 24) to 24.41, marking an increase of 11.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 316.56. This value exceeds the healthy maximum of 3. It has increased from 12.59 (Mar 24) to 316.56, marking an increase of 303.97.
- For EV / EBITDA (X), as of Mar 25, the value is -92.45. This value is below the healthy minimum of 5. It has decreased from 20.24 (Mar 24) to -92.45, marking a decrease of 112.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 383.23. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.23, marking an increase of 361.46.
- For Price / BV (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.85 (Mar 24) to 2.46, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 383.71. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.71, marking an increase of 361.94.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Agrigenetics Ltd:
- Net Profit Margin: -395.59%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -2.42% (Industry Average ROCE: 3.57%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -2.53% (Industry Average ROE: 3.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -26.77
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 330.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 267 (Industry average Stock P/E: 116.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -395.59%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Floriculture | 806, Meghdoot, 94, Nehru Place, New Delhi Delhi 110019 | hindustanagrigenetics@gmail.com http://www.hindustanagrigenetics.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pranav Kapur | Chairman |
| Mr. Pritam Kapur | Director |
| Ms. Chandni Kapur | Director & CFO |
| Ms. Mannu Kohli | Director |
| Mr. Sunny Srivastava | Independent Director |
| Mr. Naren Parsai | Independent Director |
| Mr. Ravi Shankar Kolathur | Independent Director |